Accès ouvert
2025
conference-abstract
OpenAlex
Niels W.C.J. van de Donk, Cyrille Touzeau, Evangelos Terpos, Aurore Perrot et autres
Abstract Clinical Background. Iberdomide is a novel, potent, oral CELMoD with clinically meaningful activity and favorable toxicity profile in patients (pts) with MM, including those with newly diagnosed and IMiD-refractory disease. We previously showed that iberdomide maintenance improves response post-transplant with a …
nl, fr, gr, it, pk, us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Aurore Perrot, Cyrille Hulin, Stéphanie Harel, Veronique Vitry et autres
Abstract Introduction Teclistamab was the first approved BCMAxCD3 bispecific antibody for the treatment of patients with relapsed refractory multiple myeloma (RRMM) previously exposed to a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody based on the data from MajesTEC-1 …
fr, es
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Salomon Manier, Jérôme Lambert, M. Macro, Thomas Chalopin et autres
Abstract Background. Teclistamab is a subcutaneous bispecific IgG4 antibody targeting BCMA on myeloma cells and CD3 on T cells, enabling T-cell–mediated cytotoxicity. Daratumumab is an anti-CD38 monoclonal antibody used in combination with standard agents. The current standard-of-care regimens in elderly patients with …
fr, us, ie, it
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Cecile Sonntag Mottier, Joris Mallard, Charline Fuseau, Mathieu Baldacini et autres
Abstract Background Multiple myeloma (MM) patients have been first excluded from exercise programs due to their pain and fracture risk. However, recent therapeutic advances have improved their prognosis and symptom control, making exercise feasible and well-tolerated. Before implementing exercise program in MM …
fr
(code pays fourni par la source)